• Users Online: 580
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
SHORT COMMUNICATION
Year : 2012  |  Volume : 3  |  Issue : 2  |  Page : 82-84

Newborn Screening for Hemoglobin Disorders and G6PD deficiency: A National Strategy Toward a Uniform Screening Panel and System


Department of Pediatric Hematology/Oncology, King Abdul Aziz University Hospital, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Newborn screening (NBS) programs help identify serious disease conditions that can lead to mortality, morbidity, and disability and can be controlled only after detection. The purpose of NBS is identifying infants with clinically significant disorders, providing them with specialized care, and educating parents at an early stage before the onset of clinical symptoms. The efficiency and effectiveness of NBS depends on the smooth integration of sample collection, laboratory testing, follow-up, diagnosis, timely treatment, management, and tracking of outcomes. NBS began in the early 1960s with the original work of Dr. Robert Guthrie, who developed a screening test for phenylketonuria and a system for the collection and transportation of blood samples on filter paper[1]. NBS has been nationally recognized as an essential program that aims to ensure the best outcomes for the nation's newborn population. However, there are no defined national standards for NBS[1-6].. In 2000, the Newborn Task Force of the American Academy of Pediatrics (AAP) indicated that uniformity among programs would benefit families, professionals, and public health agencies[7]. Neonatal screening programs are effective when they are integrated into comprehensive follow-up services and coupled with parental education and support. Hemoglobin disorders and glucose-6-phosphate dehydrogenase (G6PD) deficiency are the common disorders that affect newborns in the Kingdom of Saudi Arabia, and the incidence of these diseases has shown wide geographical variation[ 8-12]. NBS for sickle cell disorders (SCDs) and G6PD deficiency was introduced in the Kingdom of Saudi Arabia in the early 1980s[13-14]. The primary objective of neonatal screening is to identify infants with clinically significant disorders such as SCD, thalassemia major, and G6PD deficiency and provide comprehensive care and follow-up with early parental education to reduce morbidity and mortality[15-19].


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1332    
    Printed31    
    Emailed0    
    PDF Downloaded130    
    Comments [Add]    

Recommend this journal